By Marilyn T.  McGoldrick, Esq. Published on May 28, 2019 A Philadelphia jury ordered Ethicon, a subsidiary of Johnson and Johnson, to pay $80 million dollars to a woman who was injured by her Prolift transvaginal mesh implant. The verdict included an award of $50 million dollars in punitive damages. This is the 10th mesh-related… Read More


Transvaginal Mesh Sales Halted The U.S. Food and Drug Administration (FDA) has ordered makers of transvaginal surgical mesh implants to immediately stop the distribution and sale of the products in the United States. The FDA said that Boston Scientific and Coloplast, the last two companies selling these products in the U.S., have not demonstrated “a… Read More


A Pennsylvania state court jury awarded $2.16 million in damages to a woman with an Ethicon ProLift +M Pelvic Floor Repair System which eroded inside her body and cannot be removed. This is the fourth consecutive win for plaintiffs in the Philadelphia Court of Common Pleas, and the fourth multi-million dollar award against Johnson & Johnson and its subsidiary Ethicon. It is the first time punitive damages were not awarded.… Read More


The FDA has issued a final order reclassifying transvaginal mesh used to repair Pelvic Organ Prolapse (POP) from class II (moderate-risk) to class III (high-risk). The FDA will also require manufacturers of every surgical mesh used to treat POP to conduct a PreMarket Approval application demonstrating the safety and effectiveness of their mesh product for treating POP. Manufacturers have 30 months — two and one half years — to show that their products are safe and effective for POP. These new FDA orders do not apply to mesh sold for Stress Urinary Incontinence (SUI) or abdominal repair.… Read More